Table 1.
Clinical and demographic characteristics of patients undergoing CDK4/6 inhibitor therapy.
| N° of Patients out of 160 (%) | Characteristics |
|---|---|
| Age at the start of CDK4/6i therapy | |
| 82 (51.26%) | 70–75 |
| 78 (48.74%) | >75 |
| Age at the diagnosis | |
| 89 (55.63%) | ≤75 |
| 71 (44.37%) | >75 |
| Stage at the diagnosis | |
| 51 (31.87%) | I–III |
| 109 (68.13%) | IV |
| N° metastasis sites | |
| 55 (34.37%) | Soft tissue/bone |
| 105 (65.63%) | Visceral |
| BC subtype | |
| 90 (56.25%) | Luminal A |
| 70 (43.75%) | Luminal B |
| Comorbidities | |
| 6 (3.76%) | 0 |
| 123 (76.87%) | 1 |
| 31 (19.37%) | 2 or more |
| ECOG PS | |
| 40 (25.00%) | 0 |
| 81 (50.63%) | 1 |
| 39 (24.37%) | 2 |
| G8 score | |
| 87 (54.37%) | >14 |
| 73 (45.63%) | ≤14 |
| Endocrine therapy | |
| 100 (62.50%) | Letrozole or Anastrozole |
| 60 (37.50%) | Fulvestrant |
| CDK4/6i | |
| 49 (30.62%) | Abemaciclib |
| 58 (36.25%) | Palbociclib |
| 53 (33.13%) | Ribociclib |
| Starting dose | |
| 86 (53.75%) | Standard |
| 74 (46.25%) | Reduced |
| Dose reduction | |
| 61 (38.13%) | Yes |
| 99 (61.87%) | No |
| Toxicities | |
| 35 (21.87%) | G1 |
| 44 (27.50%) | G2 |
| 46 (28.75%) | G3 |
| 75 (46.87%) | Temporary suspensions |
| 28 (17.5%) | 1 |
| 23(14.37%) | 2 |
| 30 (18.75%) | 3 |
| BMI | |
| 60 (37.5%) | BMI < 25 |
| 100 (62.5%) | BMI ≥ 25 |
| 15 | MEDIAN PFS |
| 19 | MEDIAN OS |